scispace - formally typeset
R

Rahul N. Khurana

Researcher at University of California, San Francisco

Publications -  93
Citations -  2024

Rahul N. Khurana is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Visual acuity & Macular edema. The author has an hindex of 20, co-authored 85 publications receiving 1331 citations. Previous affiliations of Rahul N. Khurana include University of Southern California & University of California.

Papers
More filters
Journal ArticleDOI

Syphilis: reemergence of an old adversary.

TL;DR: Ocular findings, including posterior placoid chorioretinitis, are important diagnostic features in the early treatment of tertiary syphilis and neurosyphilis, and ophthalmologists have the opportunity to play a key role in theEarly diagnosis and management of this potentially fatal disease.
Journal ArticleDOI

Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.

TL;DR: Absence of lens capsule and prior vitrectomy are risk factors for migration of the DEX implant into the anterior chamber and early removal of the implant may be necessary to minimize the risk of chronic corneal edema.
Journal ArticleDOI

High-speed optical coherence tomography of corneal opacities

TL;DR: Optical coherence tomography provides consistent pachymetry mapping, whereas Orbscan II significantly underestimates corneal thickness in the presence of central cornea scars.
Journal ArticleDOI

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jeffrey S. Heier, +307 more
- 01 Jan 2022 - 
TL;DR: Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD.
Journal ArticleDOI

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Charles C. Wykoff, +385 more
- 01 Jan 2022 - 
TL;DR: Robust vision gains and anatomical improvements with faricimab were achieved with adjustable dosing up to every 16 weeks, demonstrating the potential for faricIMab to extend the durability of treatment for patients with diabetic macular oedema.